1 tracked superinvestor hold IMMUNOVANT INC (IMVT), worth $4M combined, led by David Einhorn. Smart money is holding IMVT as of the latest 13F filings.
Current price
$39.25
+143.5%
1Y
Immunovant, Inc. is a biopharmaceutical firm in the clinical development phase, dedicated to advancing novel monoclonal antibody therapies for the treatment of various autoimmune conditions. The company's primary focus is batoclimab, a pioneering, fully human monoclonal antibody. This antibody is engineered to specifically target and block the neonatal fragment crystallizable receptor (FcRn), a…
Market cap
$5.5B
P/E
-10.16
Div yield
0.0%
Revenue YoY
0.0%
Analyst target
$40
Snapshot for context. For deep analysis use a stock screener — this page is about who owns it.
Superinvestors holding
1
tracked 13F / N-PORT funds
Combined value
$4M
disclosed long exposure
Tier-1 conviction
1
concentrated holders
Net this quarter
0
0 buying · 0 selling
Smart money is holding IMVT steady this quarter — buys and sells are balanced.
IMMUNOVANT INC (IMVT) is held by 1 tracked funds worth $4M combined, 1 of them concentrated Tier-1 managers whose positions carry real conviction.
The largest position belongs to David Einhorn at 0.1% of their book — no single tracked manager treats it as an outsized, top-weighted bet.
Tracked holders were largely static this quarter — no new opens, adds or trims of size — suggesting the position is being held rather than actively traded.
| Investor | Move | % of their portfolio | Position value |
|---|---|---|---|
| Held | 0.1% | $4M |
Tier badge = signal quality: 1 concentrated conviction · 2 quant/multi (context) · 3 retail & diversified. Only Tier 1 holdings feed the consensus signal.
3 insiders filed SEC Form 144 for $3M of proposed sales in the last 90 days. A 144 is filed before the trade — see who else is selling.
| Insider | Role | Shares | Value | Filed |
|---|---|---|---|---|
| Jay S Stout | Officer | 40,000 | $2M | 2026-06-26 |
| Chris Adair Van Tuyl | Officer & Director | 17,824 | $683K | 2026-06-26 |
| Melanie Gloria | Officer | 17,714 | $679K | 2026-06-26 |
Which superinvestors own IMVT?
1 tracked funds hold IMMUNOVANT INC (IMVT), the largest being David Einhorn (Greenlight Capital) at 0.1% of its 13F portfolio. 1 of them are concentrated Tier-1 conviction managers.
Is smart money buying or selling IMVT?
In the most recent 13F quarter, 0 tracked funds added or opened IMVT and 0 trimmed it.
How much IMVT do tracked funds hold?
Combined disclosed long exposure to IMVT across tracked superinvestors is $4M as of the Jun 2026 filings.
One email when a tracked manager opens, adds to or files to sell a position — from Form 4, 13D and Form 144, not the 45-day-old 13F.
Holdings aggregated from the latest SEC 13F & N-PORT filings via FMP · Jun 2026 quarter. Long equity positions only, reported with up to a 45-day delay — for activity between filings see real-time moves. Not financial advice.